
Substantial evidence demonstrates a link of increased plasminogen activator inhibitor-1 (PAI-1) and glomerulosclerosis and kidney fibrosis, providing a novel therapeutic option for prevention and treatment of chronic kidney diseases. Several mechanisms contributing to increased PAI-1 will be addressed, including classic key profibrotic factors such as the renin-angiotensin-system (RAS) and transforming growth factor-beta (TGF-b???and novel molecules identified by proteomic analysis, such as thymosin- b4. The fibrotic sequelae caused by increased PAI-1 in kidney depend not only on its classic inhibition of tissue-type and urokinase-type plasminogen activators (tPA and uPA), but also its influence on cell migration.
Angiotensins, Fibrosis, Renin-Angiotensin System, Thymosin, Transforming Growth Factor beta1, Disease Models, Animal, Mice, Organ Specificity, Chronic Disease, Plasminogen Activator Inhibitor 1, Animals, Humans, Kidney Diseases, Oligopeptides
Angiotensins, Fibrosis, Renin-Angiotensin System, Thymosin, Transforming Growth Factor beta1, Disease Models, Animal, Mice, Organ Specificity, Chronic Disease, Plasminogen Activator Inhibitor 1, Animals, Humans, Kidney Diseases, Oligopeptides
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 85 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
